WiCell

2025 was a year of significant momentum for stem cell research and translational medicine. At WiCell, this progress was marked by our first full year of operations in our dedicated cGMP laboratory, the continued expansion of our stem cell catalog, and the addition of new capabilities like our oncopanel assay focused on genomic integrity and start-to-clinic readiness.

As we look toward 2026, our focus remains on providing the starting materials, characterization services, and continuity required for your research.

Read the recap of our 2025 milestones and a look at where we're headed for the coming year in the year-end blog from our CEO, Robert Drape.

WiCell’s 2025 Year in Review » WiCell WiCell provides the stem cell community with high-quality cell lines as well as accurate and reliable characterization testing.